ACT - アカシア・リサ―チ (AdvisorShares Vice ETF)

ACTのニュース

   Enact Holdings, Inc. 2021 Q4 - Results - Earnings Call Presentation  2022/02/02 17:28:35 Seeking Alpha
   Enact Holdings Inc Shares Approach 52-Week High - Market Mover  2022/01/17 00:22:46 Kwhen Finance
Enact Holdings Inc (ACT) shares closed today at 1.6% below its 52 week high of $22.71, giving the company a market cap of $3B. The stock is currently up 8.1% year-to-date, up 15.2% over the past 12 months, and up 15.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 39.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -963.4% The company's stock price performance over the past 12 months beats the peer average by -883.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Enact Holdings Inc Shares Approach 52-Week High - Market Mover  2022/01/15 10:42:35 Kwhen Finance
Enact Holdings Inc (ACT) shares closed today at 1.6% below its 52 week high of $22.71, giving the company a market cap of $3B. The stock is currently up 8.1% year-to-date, up 15.2% over the past 12 months, and up 15.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 39.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -963.4% The company's stock price performance over the past 12 months beats the peer average by -827.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Enact Holdings Inc Shares Close in on 52-Week High - Market Mover  2022/01/14 01:57:43 Kwhen Finance
Enact Holdings Inc (ACT) shares closed today at 1.9% below its 52 week high of $22.71, giving the company a market cap of $3B. The stock is currently up 8.2% year-to-date, up 15.3% over the past 12 months, and up 15.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 21.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -5238.0% The company's stock price performance over the past 12 months beats the peer average by -655.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Enact Holdings Inc Shares Approach 52-Week High - Market Mover  2022/01/13 03:06:32 Kwhen Finance
Enact Holdings Inc (ACT) shares closed today at 1.5% below its 52 week high of $22.71, giving the company a market cap of $3B. The stock is currently up 6.0% year-to-date, up 13.1% over the past 12 months, and up 13.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 42.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1566.4% The company's stock price performance over the past 12 months beats the peer average by -566.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Asia Pacific Breast Implants Market Expected to Expand at a Steady 2021-2028 | Allergan, Plc (Actavis Plc), Mentor Worldwide LLC. (Johnson & Johnson Services, Inc.)  2021/11/30 11:23:20 OpenPR
Market Overview: A breast implant, also called an augmentation mammoplasty, is a prosthetic device used to alter the shape, size, and tone of a woman''s breast. This procedure involves the insertion of artificial implants into the breast to improve upon a
   Contraceptives Market revenue to cross USD 39 Bn by 2027: Global Market Insights Inc.  2021/11/29 12:30:00 Intrado Digital Media
Major contraceptives market players include Pfizer, Teva Pharmaceutical Industries, Merck & Co., Mayer Laboratories, Reckitt Benckiser, Cooper Surgical, Church & Dwight Co., and Actavis. Major contraceptives market players include Pfizer, Teva Pharmaceutical Industries, Merck & Co., Mayer Laboratories, Reckitt Benckiser, Cooper Surgical, Church & Dwight Co., and Actavis.
   Anti-Osteoporosis Therapy and Fracture Healing Industry to Reach F.Hoffmann La Roche Ltd.,Actavis plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd. million by 2026  2021/11/29 04:39:42 OpenPR
Anti-Osteoporosis Therapy and Fracture Healing Market The global anti-osteoporosis therapy and fracture healing market accounted for over USD 22,400 million in 2017 and is expected to grow at a CAGR of 8.4 % during the forecast period, 2019-2026. Osteoporosis therapy is commonly
   Analyst Downgrades 2 Mortgage Insurers, Names Top Stock Pick  2021/11/17 20:16:00 Benzinga
Now that third-quarter earnings season is over for the mortgage insurance, one analyst refreshed his coverage for the group on Wednesday, including issuing two downgrades. The Analyst: Bank of America analyst Mihir Bhatia issued the following changes to his mortgage insurance coverage: MGIC Investment Corp. (NYSE: MTG ) downgraded from Buy to Neutral, price target raised from $16 to $16.50. Radian Group Inc (NYSE: RDN ) downgraded from Buy to Underperform, price target cut from $25 to $22.50. Enact Holdings Inc (NASDAQ: ACT ) reiterated at Neutral, price target raised from $23 to $23.50. Essent Group Ltd (NYSE: ESNT ) reiterated at Buy, price target reiterated at $53. Related Link: Is The US Entering A Millennial Baby … Full story available on Benzinga.com
   Taconic Capital Advisors LP Buys Enact Holdings Inc, Enact Holdings Inc, Biogen Inc, Sells , , ...  2021/11/15 19:38:12 GuruFocus
Related Stocks: BIIB , RCI , VICI , CVS , WLTW , ODP , ACT , ACT , XEC , GE , HPLTU , ALX , ALXN , WORK , BABA , MXIM , HIG , CNC ,
   Enact Holdings EPS beats by $0.04, beats on revenue  2021/11/02 20:53:58 Seeking Alpha
   Liposarcoma Treatment Market Growth, Trends, COVID-19 Impact, and Forecasts (2021 2027)| Johnson & Johnson, Pfizer, Eli Lilly, Sanofi SA, Novartis AG, Baxter International, Bristol Laboratories, Teva Pharmaceutical Industries, Mylan N.V, Actavis, Fresenius Kabi, Accord Healthcare, Taro Pharmaceuticals, Sandoz  2021/10/29 10:39:18 Jumbo News
The latest Liposarcoma Treatment market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thorough analysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. Request a sample on []
   Opioids Market to Witness an Explicit Growth Globally 2021-2028 | Top Players : Pfizer, Boehringer Ingelheim, Janssen Pharmaceuticals, Actavis  2021/10/27 08:02:51 OpenPR
New Study Reports Opioids Market 2021, Global Key Players Analysis, Share, Trends, Business Updates, Future Opportunities Forecasts to 2028 has been Added. In terms of revenue, the global Opioids market was valued at US$ 13,697.6 Mn in 2020
   Transdermal Drug Delivery System Market 2021 Growing Demand, Size and Business Outlook - Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), Johnson & Johnson, Lohmann  2021/10/26 11:40:22 OpenPR
The "Transdermal Drug Delivery System" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Transdermal Drug Delivery System Industry presents a market overview,
   The Sham Litigation Exception after AbbVie - Is the Subjective Element a Sham?  2021/10/20 19:55:30 JD Supra
The Federal Trade Commission (FTC) sued AbbVie and Besins Healthcare, co-owners of a patent that covered brand AndroGel, in 2017. The FTC claimed that the manufacturers had brought sham patent infringement litigation in 2011 against Teva and another generic supplier, Perrigo. AndroGel is a blockbuster testosterone replacement therapy. The FTC also claimed that the December 2011 Teva settlement constituted an illegal reverse payment settlement under FTC v. Actavis, in violation of Section 5 By: Haug Partners LLP

calendar